Timber Pharmaceutical Gets FDA Fast Track designation for TMB-001 in Severe Subtypes of Congenital Ichthyosis

Timber Pharmaceuticals, Inc. (NYSE:TMBR)  announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TMB-001 for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI).

The company concluded the Phase 2b CONTROL study evaluating TMB-001 in moderate to severe congenital ichthyosis (CI).